Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

ABEO

Abeona Therapeutics Inc

Feb 13 • 04:00PM ET

5.01

+0.02 0.40 %

Healthcare • Biotechnology • USA • NASD

Peers: BMRN QURE SRPT SGMO BLUE CLGN ADVM FATE VYGR NTLA

| Held by: VTI IWM VXF SURI IWO VTWO FESM IWC ITOT EES

Index	RUT	P/E	4.30	EPS (ttm)	1.17	Insider Own	10.28%	Shs Outstand	52.40M	Perf Week	-2.34%
Market Cap	271.50M	Forward P/E	-	EPS next Y	-0.14	Insider Trans	-5.48%	Shs Float	48.62M	Perf Month	-3.47%
Enterprise Value	88.15M	PEG	-	EPS next Q	-0.35	Inst Own	59.12%	Short Float	29.48%	Perf Quarter	1.42%
Income	82.35M	P/S	678.75	EPS this Y	176.77%	Inst Trans	7.32%	Short Ratio	10.63	Perf Half Y	-30.71%
Sales	0.40M	P/B	1.53	EPS next Y	-111.93%	ROA	46.83%	Short Interest	14.33M	Perf YTD	-4.93%
Book/sh	3.27	P/C	1.31	EPS next 5Y	-	ROE	75.90%	52W High	7.54 -33.56%	Perf Year	-15.51%
Cash/sh	3.83	P/FCF	-	EPS past 3/5Y	58.40% 47.21%	ROIC	44.19%	52W Low	3.93 27.39%	Perf 3Y	104.49%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-858.75%	Volatility	3.46% 4.96%	Perf 5Y	-93.23%
Dividend TTM	-	EV/Sales	220.38	EPS Y/Y TTM	168.08%	Oper. Margin	-20802.25%	ATR (14)	0.23	Perf 10Y	-91.65%
Dividend Ex-Date	-	Quick Ratio	9.53	Sales Y/Y TTM	-100.00%	Profit Margin	20587.50%	RSI (14)	46.13	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	9.74	EPS Q/Q	84.88%	SMA20	-2.29%	Beta	1.13	Target Price	21.75
Payout	-	Debt/Eq	0.14	Sales Q/Q	-	SMA50	-2.96%	Rel Volume	0.32	Prev Close	4.99
Employees	136	LT Debt/Eq	0.09	Earnings	Nov 12 BMO	SMA200	-12.00%	Avg Volume	1.35M	Price	5.01
IPO	Sep 19, 1980	Option/Short	Yes / Yes	EPS/Sales Surpr.	64.54% -100.00%	Trades		Volume	437,159	Change	0.40%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-02-25	Resumed	Oppenheimer	Outperform	$19
Mar-05-25	Initiated	Oppenheimer	Outperform	$16
Jul-03-24	Initiated	H.C. Wainwright	Buy	$15
May-30-24	Initiated	Stifel	Buy	$21
Nov-11-20	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$4
Sep-18-20	Initiated	B. Riley FBR	Buy	$5
Feb-10-20	Initiated	SVB Leerink	Outperform	$6
Dec-10-19	Resumed	Cantor Fitzgerald	Neutral	$2 → $4
Aug-15-19	Downgrade	Maxim Group	Buy → Hold
Aug-12-19	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$29 → $2
Jul-26-19	Downgrade	Mizuho	Buy → Neutral	$17 → $4
Jun-27-19	Initiated	Mizuho	Buy
Oct-12-18	Initiated	Mizuho	Buy	$17
Jun-05-18	Initiated	Seaport Global Securities	Buy	$29
Nov-08-17	Initiated	SunTrust	Buy	$26
Oct-16-17	Reiterated	H.C. Wainwright	Buy	$20 → $30
Oct-11-17	Reiterated	Cantor Fitzgerald	Overweight	$21 → $34
Oct-10-17	Initiated	Citigroup	Buy	$32
Oct-05-17	Reiterated	Maxim Group	Buy	$17 → $35
Sep-15-17	Initiated	RBC Capital Mkts	Outperform	$23

Show Previous Ratings

Today 05:00AM	Netflix Is Casting a Light on a Rare Disease. Pearl Jam's Frontman Is Raising Cash to Cure It. (Barrons.com)
Feb-09-26 10:04AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-31-25 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-15-25 07:30AM	Abeona Therapeutics Announces Appointment of Mohamad Tabrizi as Chief Business Officer (GlobeNewswire) -5.22%
Dec-11-25 07:30AM	Abeona Therapeutics Announces New Qualified Treatment Center for ZEVASKYN in Texas (GlobeNewswire)
07:30AM	Loading…
Dec-08-25 07:30AM	Abeona Therapeutics Announces First Patient Treatment with ZEVASKYN Gene Therapy (GlobeNewswire) +5.34%
Dec-01-25 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.72%
Nov-12-25 04:01PM	Abeona Therapeutics Inc (ABEO) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com) +18.47% -8.30%
11:37AM	Here's Why Abeona Therapeutics Popped Higher Today (Motley Fool)
07:40AM	Abeona Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Abeona Therapeutics Reports Third Quarter 2025 Financial Results and Corporate Updates (GlobeNewswire)
Nov-07-25 07:30AM	Abeona Therapeutics Announces Date of Third Quarter Financial Results and Upcoming Investor Conference Participation (GlobeNewswire)
Nov-03-25 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-30-25 10:45AM	Abeona Therapeutics Announces Permanent J-Code for ZEVASKYN (prademagene zamikeracel) (GlobeNewswire)
Oct-20-25 08:30AM	Abeona Therapeutics Appoints James A. Gow, MD, MBA, MS, MHCM, as Senior Vice President, Head of Clinical Development & Medical Affairs (GlobeNewswire)
07:30AM	Loading…
Oct-13-25 07:30AM	Abeona Therapeutics Announces ABO-503 Gene Therapy for X-linked Retinoschisis (XLRS) Selected by FDA for Rare Disease Endpoint Advancement (RDEA) Pilot Program (GlobeNewswire)
Oct-08-25 07:30AM	Abeona Therapeutics and Children's Hospital Colorado Announce Newest Treatment Center for ZEVASKYN Gene Therapy (GlobeNewswire) +5.52%
Oct-01-25 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-30-25 10:18AM	Krystal Biotech's Heavy Reliance on Vyjuvek: Growth Driver or Risk Factor? (Zacks)
Sep-08-25 08:28AM	Should You Invest in Abeona Therapeutics (ABEO)? (Insider Monkey)
Sep-02-25 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-29-25 07:30AM	Abeona Therapeutics Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Aug-14-25 07:38AM	Abeona Therapeutics: Q2 Earnings Snapshot (Associated Press Finance) +10.21%
07:30AM	Abeona Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates (GlobeNewswire)
Aug-11-25 06:19AM	Cell Sheet-based Gene Therapy Market Analysis and Forecast, 2025-2035 \| Abeona Therapeutics, CellSeed, J-TEC, and Holostem Lead with First-in-Class Therapies and Strong Commercialization Strategies (GlobeNewswire)
Aug-01-25 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-31-25 11:40PM	Abeona Therapeutics, AscellaHealth Partner for Commercialization of ZEVASKYN Gene Therapy (Insider Monkey) -6.32%
Jul-29-25 10:00AM	AscellaHealth HUB Partnership with Abeona Therapeutics® Supports Launch Success of Novel Cell-Based Gene Therapy and Access to Treatment for Rare Disease Patients (GlobeNewswire)
Jul-15-25 07:30AM	ZEVASKYN Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area (GlobeNewswire)
Jul-14-25 07:00AM	Bio-Techne's Simple Western Technology Utilized in Recent FDA Approval of ZEVASKYN Cell-Based Gene Therapy (PR Newswire)
07:30AM	Loading…
Jul-02-25 07:30AM	Abeona Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million (GlobeNewswire) +5.39%
Jul-01-25 07:30AM	Abeona Therapeutics Announces Option Exercise by Beacon Therapeutics for Novel AAV204 Capsid for Ophthalmology Gene Therapy (GlobeNewswire)
07:15AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-30-25 07:30AM	Abeona Therapeutics added to Membership of U.S. Small-cap Russell 2000 Index and Broad-market Russell 3000 Index (GlobeNewswire)
Jun-24-25 07:30AM	Abeona Therapeutics Announces Publication in The Lancet of Phase 3 VIITAL Study Data in Recessive Dystrophic Epidermolysis Bullosa (GlobeNewswire)
Jun-02-25 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-30-25 08:46AM	Abeona Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-15-25 07:38AM	Abeona Therapeutics: Q1 Earnings Snapshot (Associated Press Finance) +7.42%
07:30AM	Abeona Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates (GlobeNewswire)
May-14-25 08:07AM	UPDATE -- Abeona Therapeutics and Lurie Children's Open First Center for ZEVASKYN Gene Therapy to Treat Wounds in Painful Skin Disorder (GlobeNewswire)
07:30AM	Abeona Therapeutics and Lurie Children's Open First Center for ZEVASKYNTM Gene Therapy to Treat Wounds in Painful Skin Disorder (GlobeNewswire)
07:30AM	Abeona Therapeutics and Lurie Children's Open First Center for ZEVASKYN Gene Therapy to Treat Wounds in Painful Skin Disorder (GlobeNewswire)
May-13-25 07:21AM	Abeona secures cash runway with $155m priority review voucher sale (Pharmaceutical Technology)
May-12-25 07:30AM	Abeona Therapeutics Enters into Agreement to Sell Priority Review Voucher for $155 Million (GlobeNewswire) +6.26%
04:38AM	Abeona sells speedy drug review voucher for $155M (BioPharma Dive)
May-07-25 04:59PM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.51%
Apr-30-25 07:16AM	FDA approves Abeonas $3.1m cell therapy for rare skin disease (Pharmaceutical Technology) +23.77%
Apr-29-25 03:06PM	Abeona Therapeutics Wins FDA Approval For First-of-Its-Kind Gene Therapy (Benzinga)
06:00AM	U.S. FDA Approves ZEVASKYN (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB) (GlobeNewswire)
Apr-27-25 08:30AM	Undercovered Dozen: 3D Systems, Seritage, Topicus, Timken + (Seeking Alpha)
Apr-21-25 10:00AM	Pz-Cel Has Massive Potential For RDEB Patients (Seeking Alpha)
Apr-14-25 07:11AM	Abeona Therapeutics: An Uncertain Pivotal Regulatory Catalyst With Limited Long-Term Upside (Seeking Alpha) +7.61%
Apr-12-25 11:39AM	Abeona Therapeutics: A Buy With Major PDUFA Catalyst On April 29 That Should Send Shares Higher (Seeking Alpha)
Apr-06-25 08:38AM	Krystal Biotech: Some Uncertainty, Some Value (Seeking Alpha)
Apr-01-25 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.51%
Mar-21-25 03:02AM	Abeona Therapeutics Inc (ABEO) Q4 2024 Earnings Call Highlights: Strategic Advancements and ... (GuruFocus.com)
12:41AM	Q4 2024 Abeona Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-20-25 03:21PM	Abeona Therapeutics targets $2B revenue potential for pz-cel amid U.S. launch preparations (SeekingAlpha)
03:20PM	Abeona Therapeutics Inc. (ABEO) Q4 2024 Earnings Call Transcript (SeekingAlpha)
07:30AM	Abeona Therapeutics Reports Full Year 2024 Financial Results, Provides Pz-cel Regulatory Update and Commercial Launch Plans (GlobeNewswire)
Mar-04-25 09:00AM	Abeona Therapeutics to Present at the Leerink Partners Global Healthcare Conference (GlobeNewswire)
07:46AM	Abeona Therapeutics announces new employee inducement grants (TipRanks)
Mar-03-25 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-03-25 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-31-24 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-02-24 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-27-24 07:00AM	DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025 (ACCESS Newswire) +6.30%
Nov-15-24 02:06AM	Abeona Therapeutics Inc (ABEO) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
Nov-14-24 07:42AM	Abeona Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Abeona Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates (GlobeNewswire)
Nov-12-24 07:30AM	Abeona Therapeutics Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (GlobeNewswire) -5.05%
Nov-04-24 07:30AM	Abeona Therapeutics Announces Participation in November Investor Conferences (GlobeNewswire)
Nov-01-24 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-29-24 07:30AM	Abeona Therapeutics Completes Pz-cel Biologics License Application Resubmission to U.S. Food and Drug Administration (GlobeNewswire)
Oct-09-24 06:13PM	Abeona Therapeutics Inc (ABEO) Q2 2024 Earnings Call Highlights: Strong Financial Performance ... (GuruFocus.com)
Oct-01-24 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-03-24 07:30AM	Abeona Therapeutics Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Sep-02-24 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-14-24 07:30AM	Abeona Therapeutics Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of Directors (GlobeNewswire)
Aug-13-24 07:30AM	Abeona Therapeutics Announces Favorable Medicare Reimbursement Decisions for Pz-cel (GlobeNewswire)
Aug-12-24 07:37AM	Abeona Therapeutics: Q2 Earnings Snapshot (Associated Press Finance) +11.99%
07:30AM	Abeona Therapeutics Reports Second Quarter 2024 Financial Results and Concludes Type A Meeting with FDA to Align on Upcoming Pz-cel BLA Resubmission (GlobeNewswire)
Aug-01-24 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-11-24 07:30AM	Abeona Therapeutics and Beacon Therapeutics Announce Non-Exclusive Agreement for Beacon to Evaluate Therapeutic Potential of Abeona's Patented AAV204 Capsid for Select Ophthalmology Indications (GlobeNewswire)
Jul-08-24 07:30AM	Abeona Therapeutics to Present at the Stifel Virtual Cell Therapy Forum (GlobeNewswire) +5.73%
Jun-21-24 03:08AM	Insider Sale: Director Christine Silverstein Sells Shares of Abeona Therapeutics Inc (ABEO) (GuruFocus.com)
Jun-03-24 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-28-24 07:30AM	Abeona Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-16-24 03:01AM	Abeona Therapeutics Inc (ABEO) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances ... (GuruFocus.com)
02:17AM	Q1 2024 Abeona Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
May-15-24 12:53PM	ABEO Stock Earnings: Abeona Therapeutics Misses EPS for Q1 2024 (InvestorPlace) +12.14%
07:43AM	Abeona Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
07:30AM	Abeona Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Progress (GlobeNewswire)
May-07-24 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-03-24 11:19AM	Abeona Therapeutics Prices $75 Million Securities Offering; Shares Rise (MT Newswires) +13.02%
07:30AM	Abeona Therapeutics Announces Pricing of $75 Million Underwritten Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Apr-23-24 02:04PM	Top Midday Decliners (MT Newswires) -53.67%
08:53AM	Why Is Abeona Therapeutics (ABEO) Stock Down 45% Today? (InvestorPlace)
07:39AM	Top Premarket Decliners (MT Newswires)
07:09AM	FDA rejects Abeona cell therapy, asks for more manufacturing data (BioPharma Dive)

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Silverstein Christine Berni	Director	Feb 02 '26	Proposed Sale	5.09	20,070	102,168		Feb 09 04:01 PM
Silverstein Christine Berni	Director	Feb 02 '26	Sale	5.09	20,070	102,168	137,722	Feb 04 04:30 PM
Wuchterl Donald A.	Director	Feb 02 '26	Sale	5.09	14,814	75,412	167,935	Feb 02 06:59 PM
Crombez Eric	Director	Feb 02 '26	Sale	5.09	16,284	82,895	63,456	Feb 02 06:55 PM
Wuchterl Donald A.	Director	Feb 02 '26	Proposed Sale	5.09	14,814	75,412		Feb 02 04:58 PM
Crombez Eric	Director	Feb 02 '26	Proposed Sale	5.09	16,284	82,886		Feb 02 04:43 PM
Alvino Mark	Director	Feb 02 '26	Proposed Sale	5.09	2,000	10,180		Feb 02 04:40 PM
Alland Leila	Director	Feb 02 '26	Proposed Sale	5.09	18,065	91,962		Feb 02 04:39 PM
Alland Leila	Director	Feb 02 '26	Sale	5.09	18,065	91,962	173,614	Feb 02 04:30 PM
Alvino Mark	Director	Feb 02 '26	Sale	5.09	2,000	10,181	84,065	Feb 02 04:30 PM
Vasanthavada Madhav	Chief Commercial Officer	Jan 22 '26	Sale	5.29	12,610	66,658	318,619	Jan 26 04:35 PM
Vazzano Joseph Walter	Chief Financial Officer	Jan 22 '26	Sale	5.33	18,666	99,507	568,560	Jan 22 08:34 PM
Seshadri Vishwas	Chief Executive Officer	Jan 22 '26	Sale	5.33	69,832	372,267	1,460,408	Jan 22 08:33 PM
O'Malley Brendan M.	SVP, Chief Legal Officer	Jan 22 '26	Sale	5.33	13,578	72,383	451,134	Jan 22 08:33 PM
Vasanthavada Madhav	Officer	Jan 22 '26	Proposed Sale	5.29	12,610	66,658		Jan 22 04:10 PM
Vazzano Joseph Walter	Officer	Jan 22 '26	Proposed Sale	5.33	18,666	99,507		Jan 22 04:09 PM
O'Malley Brendan M.	Officer	Jan 22 '26	Proposed Sale	5.39	13,578	73,233		Jan 22 04:09 PM
Seshadri Vishwas	Officer	Jan 22 '26	Proposed Sale	5.33	69,832	372,267		Jan 22 04:08 PM
Alvino Mark	Director	Jan 21 '26	Sale	5.23	13,500	70,574	48,752	Jan 21 04:30 PM
Alvino Mark	Director	Jan 21 '26	Proposed Sale	5.23	13,500	70,574		Jan 21 04:10 PM
Seshadri Vishwas	Chief Executive Officer	Dec 29 '25	Sale	5.31	25,000	132,740	1,164,818	Dec 29 04:30 PM
Seshadri Vishwas	Officer	Dec 29 '25	Proposed Sale	5.31	25,000	132,695		Dec 29 04:00 PM
Alvino Mark	Director	Nov 13 '25	Sale	4.74	15,000	71,168	62,252	Nov 14 04:30 PM
Alvino Mark	Director	Nov 13 '25	Proposed Sale	4.74	15,000	71,168		Nov 13 04:06 PM
Seshadri Vishwas	Chief Executive Officer	Oct 16 '25	Sale	5.49	249	1,366	1,189,818	Oct 16 04:15 PM
Seshadri Vishwas	Officer	Oct 16 '25	Proposed Sale	5.49	249	1,366		Oct 16 04:09 PM
O'Malley Brendan M.	SVP, Chief Legal Officer	Sep 29 '25	Sale	5.39	9,366	50,516	350,763	Oct 01 04:30 PM
Seshadri Vishwas	Chief Executive Officer	Sep 30 '25	Sale	5.24	25,000	130,930	1,190,067	Oct 01 04:30 PM
Seshadri Vishwas	Chief Executive Officer	Sep 29 '25	Sale	5.39	19,274	103,954	1,215,067	Oct 01 04:30 PM
Vazzano Joseph Walter	Chief Financial Officer	Sep 29 '25	Sale	5.39	9,035	48,730	453,631	Oct 01 04:30 PM
Seshadri Vishwas	Officer	Sep 29 '25	Proposed Sale	5.39	44,274	238,792		Sep 29 04:54 PM
O'Malley Brendan M.	Officer	Sep 29 '25	Proposed Sale	5.39	9,366	50,516		Sep 29 04:44 PM
Vazzano Joseph Walter	Officer	Sep 29 '25	Proposed Sale	5.39	9,366	50,516		Sep 29 04:31 PM
O'Malley Brendan M.	SVP, Chief Legal Officer	Sep 22 '25	Sale	5.43	688	3,736	360,129	Sep 22 07:49 PM
O'Malley Brendan M.	Officer	Sep 22 '25	Proposed Sale	5.86	17,376	101,749		Sep 22 04:23 PM
Crombez Eric	Director	Aug 14 '25	Sale	6.93	4,718	32,683	42,427	Aug 15 04:30 PM
Vazzano Joseph Walter	Chief Financial Officer	Aug 15 '25	Sale	7.36	15,000	110,358	462,666	Aug 15 04:30 PM
Vazzano Joseph Walter	Officer	Aug 15 '25	Proposed Sale	7.36	15,000	110,358		Aug 15 04:15 PM
Vazzano Joseph Walter	Chief Financial Officer	Jul 22 '25	Sale	6.64	1,502	9,975	477,666	Jul 22 04:15 PM
Vazzano Joseph Walter	Officer	Jul 22 '25	Proposed Sale	6.64	1,502	9,975		Jul 22 04:11 PM
Silverstein Christine Berni	Director	Jul 09 '25	Sale	5.86	13,093	76,669	120,479	Jul 10 04:30 PM
Seshadri Vishwas	Chief Executive Officer	Jul 09 '25	Sale	5.86	69,420	406,503	1,234,341	Jul 10 04:30 PM
Vazzano Joseph Walter	Chief Financial Officer	Jul 09 '25	Sale	5.86	25,411	148,799	479,168	Jul 10 04:30 PM
Wuchterl Donald A.	Director	Jul 08 '25	Sale	5.82	5,176	30,147	145,436	Jul 10 04:30 PM
Charles Faith L.	Director	Jul 09 '25	Sale	5.86	10,738	62,879	139,094	Jul 10 04:30 PM
O'Malley Brendan M.	SVP, Chief Legal Officer	Jul 09 '25	Sale	5.86	17,428	102,053	360,817	Jul 10 04:30 PM
Alvino Mark	Director	Jul 09 '25	Sale	5.86	13,093	76,669	77,252	Jul 10 04:30 PM
Vazzano Joseph Walter	Officer	Jul 09 '25	Proposed Sale	5.86	25,335	148,354		Jul 09 04:55 PM
Seshadri Vishwas	Officer	Jul 09 '25	Proposed Sale	5.86	69,215	405,302		Jul 09 04:52 PM
O'Malley Brendan M.	Officer	Jul 09 '25	Proposed Sale	5.86	17,376	101,749		Jul 09 04:48 PM
Charles Faith L.	Director	Jul 09 '25	Proposed Sale	5.86	10,706	62,691		Jul 09 04:45 PM
Silverstein Christine Berni	Director	Jul 09 '25	Proposed Sale	5.86	13,054	76,440		Jul 09 04:40 PM
Alvino Mark	Director	Jul 09 '25	Proposed Sale	5.86	13,054	76,440		Jul 09 04:36 PM
Wuchterl Donald A.	Director	Jul 08 '25	Proposed Sale	5.82	5,176	30,147		Jul 08 04:06 PM
Vazzano Joseph Walter	Chief Financial Officer	Jun 06 '25	Sale	6.76	17,795	120,294	491,246	Jun 06 06:04 PM
Seshadri Vishwas	Chief Executive Officer	Jun 06 '25	Sale	6.76	50,676	342,570	1,303,761	Jun 06 06:00 PM
O'Malley Brendan M.	SVP, General Counsel	Jun 06 '25	Sale	6.76	10,470	70,777	378,245	Jun 06 05:56 PM
Vazzano Joseph Walter	Officer	Jun 06 '25	Proposed Sale	6.76	17,795	120,314		Jun 06 04:13 PM
O'Malley Brendan M.	Director	Jun 06 '25	Proposed Sale	6.76	10,470	70,789		Jun 06 04:12 PM
Seshadri Vishwas	Officer	Jun 06 '25	Proposed Sale	6.76	50,676	342,626		Jun 06 04:11 PM
Alvino Mark	Director	May 27 '25	Sale	6.38	2,000	12,760	90,435	May 27 07:57 PM
Alvino Mark	Director	May 27 '25	Proposed Sale	6.38	2,000	12,762		May 27 04:40 PM
Alvino Mark	Director	May 16 '25	Sale	5.68	8,000	45,440	92,435	May 16 05:23 PM
Alvino Mark	Director	May 16 '25	Proposed Sale	5.68	8,000	45,423		May 16 04:07 PM
Seshadri Vishwas	Chief Executive Officer	Mar 31 '25	Sale	4.78	25,000	119,500	1,355,322	Mar 31 07:17 PM
Seshadri Vishwas	Officer	Mar 31 '25	Proposed Sale	4.78	25,000	119,560		Mar 31 04:08 PM

Open in Screener

PMVP

PMV Pharmaceuticals Inc

Feb 13 • 04:00PM ET

1.11

+0.03 2.78 %

Healthcare • Biotechnology • USA • NASD

PMVP PMV Pharmaceuticals Inc daily Stock Chart

Peers: AMGN GILD MRNA BIIB INCY VRTX REGN NBIX ALNY BLUE

| Held by: VTI VXF IWC BTEC AVTM

Index	-	P/E	-	EPS (ttm)	-1.58	Insider Own	17.68%	Shs Outstand	52.99M	Perf Week	6.73%
Market Cap	59.06M	Forward P/E	-	EPS next Y	-1.43	Insider Trans	-13.75%	Shs Float	43.80M	Perf Month	-2.63%
Enterprise Value	-69.26M	PEG	-	EPS next Q	-0.41	Inst Own	54.02%	Short Float	4.23%	Perf Quarter	-21.83%
Income	-82.70M	P/S	-	EPS this Y	-35.53%	Inst Trans	6.96%	Short Ratio	7.00	Perf Half Y	-28.39%
Sales	0.00M	P/B	0.49	EPS next Y	7.28%	ROA	-46.29%	Short Interest	1.85M	Perf YTD	-11.20%
Book/sh	2.28	P/C	0.46	EPS next 5Y	2.24%	ROE	-51.87%	52W High	1.84 -39.67%	Perf Year	-21.83%
Cash/sh	2.43	P/FCF	-	EPS past 3/5Y	3.88% -14.06%	ROIC	-68.05%	52W Low	0.81 37.04%	Perf 3Y	-85.51%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	6.40% 5.79%	Perf 5Y	-97.36%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-58.47%	Oper. Margin	-	ATR (14)	0.06	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	10.76	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	47.87	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	10.76	EPS Q/Q	-6.60%	SMA20	0.05%	Beta	1.36	Target Price	7.75
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	-5.26%	Rel Volume	0.36	Prev Close	1.08
Employees	47	LT Debt/Eq	0.00	Earnings	Nov 12 BMO	SMA200	-10.92%	Avg Volume	264.42K	Price	1.11
IPO	Sep 25, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	0.62% -	Trades		Volume	94,370	Change	2.78%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-08-24	Upgrade	Oppenheimer	Perform → Outperform	$6
May-13-24	Initiated	Craig Hallum	Buy	$6
Apr-12-24	Initiated	Jefferies	Buy	$5
Dec-27-23	Initiated	Ladenburg Thalmann	Buy	$7
Mar-02-22	Upgrade	Oppenheimer	Perform → Outperform	$30
Sep-22-21	Upgrade	Goldman	Neutral → Buy	$35 → $43
Aug-19-21	Initiated	Oppenheimer	Perform
Aug-02-21	Initiated	Guggenheim	Buy	$56
Jul-29-21	Initiated	H.C. Wainwright	Buy	$63
Oct-20-20	Initiated	Goldman	Neutral	$34
Oct-20-20	Initiated	Evercore ISI	Outperform	$60
Oct-20-20	Initiated	Cowen	Outperform
Oct-20-20	Initiated	BofA Securities	Buy	$42

Show Previous Ratings

Nov-12-25 08:00AM	PMV Pharmaceuticals Reports Third Quarter 2025 Financial Results and Corporate Highlights (GlobeNewswire) +6.77%
Oct-24-25 11:39AM	PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation (GlobeNewswire)
Oct-13-25 04:01PM	PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire) +7.58%
Sep-10-25 03:10PM	Small-Cap PMV Pharmaceuticals Cancer Drug Shows Confirmed Responses In 8 Tumor Types (Benzinga) -20.63%
07:00AM	PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation (GlobeNewswire)
08:42AM	Loading…
Aug-07-25 08:42AM	PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights (GlobeNewswire)
May-23-25 04:05PM	PMV Pharmaceuticals to Participate at Upcoming Investor Conferences (GlobeNewswire)
May-09-25 08:00AM	PMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate Highlights (GlobeNewswire)
Mar-05-25 09:55AM	Here's Why PMV Pharmaceuticals (PMVP) Looks Ripe for Bottom Fishing (Zacks) +6.20%
Mar-03-25 08:00AM	PMV Pharmaceuticals Reports Full Year 2024 Financial Results and Corporate Highlights (GlobeNewswire)
Feb-11-25 08:00AM	PMV Pharmaceuticals to Participate at Upcoming Investor Conferences (GlobeNewswire)
Nov-07-24 08:00AM	PMV Pharmaceuticals Reports Third Quarter 2024 Financial Results (GlobeNewswire) +7.23%
Oct-23-24 08:00AM	PMV Pharmaceuticals Provides a Progress Update on PYNNACLE Clinical Trial (GlobeNewswire) -6.43%
Aug-08-24 08:00AM	PMV Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Progress Update on PYNNACLE Clinical Trial (GlobeNewswire)
Jun-03-24 09:55AM	Here's Why PMV Pharmaceuticals (PMVP) Could be Great Choice for a Bottom Fisher (Zacks)
07:00AM	Loading…
May-30-24 07:00AM	PMV Pharmaceuticals to Participate at Upcoming Investor Conferences in June (GlobeNewswire)
May-29-24 07:00AM	Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator (GlobeNewswire) -10.45%
May-09-24 01:54PM	PMVP Stock Earnings: PMV Pharma Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights (GlobeNewswire)
Mar-27-24 08:00AM	PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors (GlobeNewswire)
Mar-18-24 04:01PM	PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women's Cancer (GlobeNewswire) -5.11%
Mar-01-24 10:21AM	PMV Pharmaceuticals Inc (PMVP) Reports Full Year 2023 Financial Results (GuruFocus.com)
Feb-29-24 04:01PM	PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights (GlobeNewswire)
Feb-26-24 08:00AM	PMV Pharmaceuticals to Participate in the TD Cowen 44th Annual Health Care Conference (GlobeNewswire) +7.78%
Jan-18-24 04:01PM	PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway (GlobeNewswire) -5.76% -10.56%
Jan-05-24 04:01PM	PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development (GlobeNewswire) -5.94%
Nov-09-23 09:41AM	PMV Pharmaceuticals Inc (PMVP) Reports Q3 2023 Financial Results and Corporate Updates (GuruFocus.com)
08:00AM	PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Highlights (GlobeNewswire)
Oct-16-23 09:35AM	PMV Pharmaceuticals, Inc. (PMVP) Loses -70.19% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) -11.00%
Oct-12-23 12:30PM	PMV Pharmaceuticals Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a TP53 Y220C Mutation (GlobeNewswire) -47.58%
12:00PM	Loading…
Oct-11-23 12:00PM	PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and Host a KOL Webinar (GlobeNewswire) -26.01%
Oct-06-23 09:55AM	Wall Street Analysts See a 239.26% Upside in PMV Pharmaceuticals, Inc. (PMVP): Can the Stock Really Move This High? (Zacks) +6.62%
Sep-20-23 04:05PM	PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire) +9.62%
Aug-30-23 09:55AM	Wall Street Analysts Think PMV Pharmaceuticals, Inc. (PMVP) Could Surge 182.64%: Read This Before Placing a Bet (Zacks)
Aug-29-23 09:55AM	PMV Pharmaceuticals, Inc. (PMVP)'s Technical Outlook is Bright After Key Golden Cross (Zacks)
Aug-09-23 08:00AM	PMV Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Highlights (GlobeNewswire) +27.69%
Jun-06-23 04:01PM	PMV Pharmaceuticals to Participate in the Goldman Sachs Global Healthcare Conference (GlobeNewswire) +7.56%
May-10-23 08:00AM	PMV Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Highlights (GlobeNewswire) +8.33%
Apr-14-23 11:51AM	We Think PMV Pharmaceuticals (NASDAQ:PMVP) Can Afford To Drive Business Growth (Simply Wall St.)
Mar-01-23 08:00AM	PMV Pharmaceuticals Reports Full Year 2022 Financial Results and Corporate Highlights (GlobeNewswire) -14.15%
Feb-28-23 04:05PM	PMV Pharmaceuticals to Participate at Upcoming Investor Conferences in March (GlobeNewswire)
Dec-08-22 09:55AM	Does PMV Pharmaceuticals, Inc. (PMVP) Have the Potential to Rally 267% as Wall Street Analysts Expect? (Zacks)
Nov-22-22 08:00AM	PMV Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference (GlobeNewswire) +5.02%
Nov-17-22 06:18PM	15 Most Shorted Stocks Right Now (Insider Monkey)
Nov-08-22 08:00AM	PMV Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Highlights (GlobeNewswire)
Nov-05-22 09:39AM	We Think PMV Pharmaceuticals (NASDAQ:PMVP) Can Afford To Drive Business Growth (Simply Wall St.)
Nov-04-22 08:00AM	PMV Pharmaceuticals Appoints Industry Veteran Dr. Carol Gallagher to Board of Directors (GlobeNewswire)
Oct-11-22 12:00PM	PMV Pharmaceuticals, Inc. (PMVP) Upgraded to Buy: Here's What You Should Know (Zacks)
Sep-23-22 09:19AM	10 Most Shorted Stocks in September (Insider Monkey)
Aug-09-22 08:00AM	PMV Pharmaceuticals Reports Second Quarter 2022 Financial Results and Corporate Highlights (GlobeNewswire) -8.06%
Jul-19-22 09:26AM	10 Most Shorted Stocks to Watch in July (Insider Monkey) +5.81%
Jul-18-22 10:47AM	PMV Pharma, Merck Ink Clinical Trial Collaboration For Combination Study In Solid Tumors (Benzinga) -9.52%
08:00AM	PMV Pharmaceuticals Announces a Clinical Trial Collaboration with Merck to Evaluate PC14586 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors (GlobeNewswire)
Jun-08-22 08:00AM	PMV Pharmaceuticals to Participate in the Goldman Sachs Global Healthcare Conference (GlobeNewswire) -5.71%
Jun-07-22 12:00PM	PMV Pharmaceuticals Initial PC14586 Phase 1 Data Presented at ASCO Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a p53 Y220C Mutation (GlobeNewswire) -21.70%
May-29-22 08:26AM	We're Not Very Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Rate (Simply Wall St.)
May-26-22 05:05PM	PMV Pharmaceuticals Announces Initial PC14586 Phase 1 Clinical Data to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) +16.05%
May-20-22 03:04PM	Pennsylvania Biotech Center's economic impact grows to $7B as it expands in Bucks County, report finds (American City Business Journals)
May-10-22 07:30AM	PMV Pharmaceuticals Reports First Quarter 2022 Financial Results and Corporate Highlights (GlobeNewswire) +9.66%
Apr-27-22 10:30AM	PMV Pharmaceuticals to Present PC14586 Phase 1 Clinical Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Mar-01-22 07:15AM	PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights (GlobeNewswire) +5.11%
Feb-28-22 08:00AM	PMV Pharmaceuticals to Participate in the 42nd Annual Cowen Health Care Conference (GlobeNewswire)
Feb-03-22 08:00AM	PMV Pharmaceuticals to Participate in the Guggenheim Healthcare Talks 2022 Oncology Day (GlobeNewswire)
Jan-12-22 12:20PM	Do Hedge Funds Love PMV Pharmaceuticals, Inc. (PMVP)? (Insider Monkey)
Jan-06-22 08:00AM	PMV Pharma Announces Changes to its Board of Directors (GlobeNewswire) -16.31%
Dec-20-21 10:28AM	We're Hopeful That PMV Pharmaceuticals (NASDAQ:PMVP) Will Use Its Cash Wisely (Simply Wall St.)
Nov-22-21 08:00AM	PMV Pharma to Present at the Evercore ISI 4th Annual HealthCONx Conference (GlobeNewswire)
Nov-12-21 07:15AM	PMV Pharmaceuticals Reports Third Quarter 2021 Financial Results and Corporate Highlights (GlobeNewswire)
Oct-05-21 11:33AM	Pmv Pharmaceuticals Insider Trades $440K In Company Stock (Benzinga)
Sep-27-21 09:26PM	Goldman Sachs: Buy These 2 Stocks Before They Jump 40% (or More) (TipRanks)
Sep-09-21 08:00AM	PMV Pharmaceuticals Appoints Tim Smith as Senior Vice President, Head of Corporate Development (GlobeNewswire)
Sep-02-21 08:00AM	PMV Pharmaceuticals to Present at the Morgan Stanley 19th Annual Global Healthcare Conference (GlobeNewswire)
Aug-13-21 08:00AM	PMV Pharmaceuticals Reports Second Quarter 2021 Financial Results and Corporate Highlights (GlobeNewswire)
Jul-19-21 06:19PM	Where Do Hedge Funds Stand On PMV Pharmaceuticals, Inc. (PMVP)? (Insider Monkey)
Jun-23-21 05:38AM	We're Hopeful That PMV Pharmaceuticals (NASDAQ:PMVP) Will Use Its Cash Wisely (Simply Wall St.)
Jun-09-21 08:00AM	PMV Pharmaceuticals Announces Participation at the Bank of America Securities 2021 Napa Biopharma Virtual Conference (GlobeNewswire)
Jun-03-21 08:00AM	PMV Pharmaceuticals Announces Participation at the Goldman Sachs Annual Healthcare Conference (GlobeNewswire)
May-14-21 08:00AM	PMV Pharmaceuticals Reports First Quarter 2021 Financial Results and Corporate Highlights (GlobeNewswire) +10.54%
May-05-21 08:00AM	PMV Pharmaceuticals Announces Participation at the Bank of America Healthcare Conference (GlobeNewswire)
Apr-10-21 01:31PM	PMV Pharma Presents Late-Breaking Preclinical Data on Lead Product Candidate PC14586 at the American Association for Cancer Research Annual Meeting 2021 (GlobeNewswire)
Apr-06-21 08:00AM	PMV Pharma Strengthens Board of Directors with Appointment of Dr. Charles Baum (GlobeNewswire)
Mar-10-21 04:31PM	PMV Pharmaceuticals Announces Presentation of PC14586 Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2021 (GlobeNewswire) +12.26%
Mar-03-21 04:01PM	PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights (GlobeNewswire)
Feb-16-21 08:00AM	PMV Pharma Appoints p53 Pioneer Dr. Guillermina Lozano to Scientific Advisory Board (GlobeNewswire) -9.57%
Dec-25-20 03:44AM	We're Not Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn (Simply Wall St.)
Dec-16-20 03:19PM	Is PMVP A Good Stock To Buy Now? (Insider Monkey)
Nov-24-20 05:00PM	PMV Pharmaceuticals to Present at Evercore ISI 3rd Annual HealthCONx Conference (GlobeNewswire) +8.67%
Nov-23-20 08:00AM	PMV Pharma Doses First Patient in Phase 1/2 Study of PC14586, a First-in-Class Precision Oncology Therapy That Targets Mutant p53 (GlobeNewswire)
Nov-13-20 08:00AM	PMV Pharmaceuticals Reports Third Quarter 2020 Financial Results and Corporate Highlights (GlobeNewswire) -5.50%
Oct-13-20 08:00AM	PMV Pharma Granted FDA Fast Track Designation of PC14586 for the Treatment of Advanced Cancer Patients that have Tumors with a p53 Y220C Mutation (GlobeNewswire)
Oct-09-20 03:41PM	Janus Henderson and PMV Pharmaceuticals See Activist Action (Barrons.com)
Oct-01-20 11:57AM	Biotech Pulmonx Shares Climb in Trading Debut (Barrons.com)
Sep-29-20 04:05PM	PMV Pharma Announces Closing of $243.5 Million Initial Public Offering and Exercise in Full of Underwriters Option to Purchase Additional Shares (GlobeNewswire) +5.00% -6.58%
Sep-25-20 02:31PM	PMV Pharma Soars 115% as Biotech IPOs Take Off (Barrons.com)
12:37PM	PMV Pharmaceutical's stock nearly doubles in its debut (MarketWatch)
06:16AM	PMV Pharmaceuticals prices IPO at top end of expectations, raises $211.8 million (MarketWatch)
Sep-24-20 08:06PM	PMV Pharma Announces Pricing of Initial Public Offering (GlobeNewswire)

PMV Pharmaceuticals, Inc. is a precision oncology company, which engages in the discovery and development of small molecule, tumor-agnostic therapies targeting p53. The company was founded by Arnold J. Levine, David Henry Mac, and Thomas E. Shenk in March 2013 and is headquartered in Princeton, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mack David Henry	President and CEO	Oct 27 '25	Option Exercise	1.37	220,643	302,281	451,109	Oct 29 04:11 PM
ORBIMED ADVISORS LLC	10% Owner	Oct 23 '25	Sale	1.52	1,000,000	1,520,000	4,975,291	Oct 27 05:19 PM
OrbiMed Private Investments V,	Shareholder	Oct 23 '25	Proposed Sale	1.52	1,000,000	1,520,000		Oct 23 06:39 PM
ORBIMED ADVISORS LLC	10% Owner	Sep 10 '25	Sale	1.80	500,000	900,000	5,975,291	Sep 12 05:09 PM
OrbiMed Private Investments V,	Shareholder	Sep 10 '25	Proposed Sale	1.60	2,283,654	3,653,846		Sep 10 06:50 PM
Ticktin Robert	General Counsel & COO	Jul 01 '25	Sale	1.06	23,151	24,651	98,695	Jul 03 07:51 PM
Jalota Deepika	Chief Development Officer	Jul 01 '25	Sale	1.06	33,065	35,198	89,959	Jul 03 07:50 PM
Carulli Michael	Chief Financial Officer	Jul 01 '25	Sale	1.06	28,249	30,077	60,146	Jul 03 07:49 PM
Mack David Henry	President and CEO	Jul 01 '25	Sale	1.06	58,411	62,179	536,133	Jul 03 07:48 PM

ABEO

Abeona Therapeutics Inc

PMVP

PMV Pharmaceuticals Inc

Upgrade your FINVIZ experience